WO1997017976A1 - Microcellulose-based preparations - Google Patents

Microcellulose-based preparations Download PDF

Info

Publication number
WO1997017976A1
WO1997017976A1 PCT/EP1996/004961 EP9604961W WO9717976A1 WO 1997017976 A1 WO1997017976 A1 WO 1997017976A1 EP 9604961 W EP9604961 W EP 9604961W WO 9717976 A1 WO9717976 A1 WO 9717976A1
Authority
WO
WIPO (PCT)
Prior art keywords
microcellulose
fibres
preparations
intestinal
effect
Prior art date
Application number
PCT/EP1996/004961
Other languages
French (fr)
Inventor
Francesco Saverio Dioguardi
Original Assignee
White Swan B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by White Swan B.V. filed Critical White Swan B.V.
Priority to AU76232/96A priority Critical patent/AU7623296A/en
Priority to EP96939020A priority patent/EP0861083A1/en
Priority to JP9518574A priority patent/JP2000502048A/en
Publication of WO1997017976A1 publication Critical patent/WO1997017976A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/262Cellulose; Derivatives thereof, e.g. ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals

Definitions

  • dietary fibres the main indigestible alimentary constituent
  • dietary fibres have found a wide application in the treatment of constipation.
  • the term dietary fibres is referred to the total natural fibrosic contents available in aliments, mainly of vegetable origin, which cannot be chemically digested by the enzymatic system of humans.
  • classification of dietary fibres is referred to the residues of indigestible vegetables and can be summarized as follows:
  • Cellulose is a polysaccharide (C 6 H ⁇ o0 5 ) whose molecular weight ranges from 300.000 to 500.000, formed by linear chains of D- glucose molecules linked together by beta bonds.
  • Alimentary fibres consist of millions of cellulose molecules linked together in chains, whose length may even reach several tens of centimeters or meters. Beta bonds are undigested by mammals " enzymatic systems (for instance, starch has alpha bonds).
  • Cellulose is the main structural constituent of vegetable cell walls. It is insoluble in distilled water and acids.
  • Non-cellulosic fibres consist of non-cellulosic polysaccharides comprising emicelluloses, pectines, mucillages and other media derived by algae, resins and lignin. Besides water absorption, non-cellulosic fibres have also other collateral effects due to their chelant action as they seem to be able to chelate biliary salts and cholesterol, thus reducing their abso ⁇ tion; however, this effect is unfortunately reached also with drugs and minerals, such as iron, calcium and zinc. Further, resins and soluble fibres contained therein may undergo a bacterial digestion in the colon, and elicit short-chain volatile fat acids and gas production (carbon dioxide and methane).
  • Methyl-cellulose and carboxymethyl-cellulose derived from it are products obtained by synthesis, which modify the chemical- physical characteristics of cellulose, i.e. from insoluble to soluble in cold water and insoluble in hot water.
  • Solubility is a function of the number of methylic units used as substituents; the products known on the market have a 1,8 substitution degree, i.e. they contain about 29% methossilic units.
  • Methyl-cellulose and carboxymethyl-cellulose can be converted into gel.
  • microcellulose to be vehiculated in pharmaceutical forms suitable for ingestion tablettes, granular or powder form, etc.
  • ingestion tablettes, granular or powder form, etc.
  • preparations suitable to cover either partially or totally the requirements of alimentary fibres in humans or animals or in preparations to regulate intestinal transit, preferably suitable for the use in all conditions of altered intestinal motility due to an insufficient or viceversa excessive water retention, first in the alimentary bolus and then in stools, where microcellulose affects in a regulatory manner the solid-fluid ratio during intestinal transit.
  • Microcrystalline cellulose or microcellulose is a preparation of fragments of cellulose crystallite units in the form of a non fibrosic powder, containing particles in the form of rigid small bars, whose refraction index is 1.55.
  • the molecular weight of the basic component, microcellulose can range as required from 10.000 to 300.000, i.e. between a range of numbers of atoms classified from 10 4 to IO 9 , whose dimensions allow a liophile colloidal dispersion.
  • Availability of different molecular weights of microcrystalline cellulose allow to graduate the number of molecule in any given unit of weight, thus to improve or reduce the osmolar effect ofthe product. Examples of how microcrystalline cellulose is synthesised are described in US Patents nos. 2,978,476 and US 3,141,875.
  • Microcrystalline cellulose or microcellulose is featured by its peculiar property of being slightly soluble in diluted alcaline solutions, whereas it is totally insoluble in acids and does not gelify under any conditions.
  • microcellulose is fully inactive in the stomach and just a light solubility can be foreseen in the continuation of the gastrointestinal transit with pH raise. Moreover, unlike methyl- cellulose, microcrystalline cellulose will not dissolve in any water volume.
  • microcellulose to obtain a regulatory effect on intestinal motility due to its chemical-physical characteristics. This has the pu ⁇ ose of obviating to the problems caused by alimentary fibres available so far on the market, such as subordination to water volume, digestion of part of their constituents and often unendurable production of large intestinal gas volumes, their chelating effect con pharmaceutical products and some minerals salts.
  • microcellulose is provided for use under those conditions where alimentary fibres are not tolerated, being excessively irritant and eliciting a too fast, frequent and irritant intestinal transit of bolus volume. Microcellulose is not digested by mammals because they have no cellulase, i.e. the enzyme required to break beta bonds between D- glucose molecules. For this reason, microcellulose will not cause, as of itself, any problems related to the digestion of sugars contained in the fibres or alimentary fibres. 7
  • microcellulose Due to the relatively small molecular size in respect to cellulosic fibres (containing milions of closely interlaced cellulose units for total macroscopic sizes), microcellulose is also featured by a lower water eagerness and unlike water soluble methyl-cellulose it is insoluble in water.
  • microcellulose will yield a number of molecules as liophile dispersion to the water available with or contained in the aliments, as a fixed proportion of the water- microcellulose ratio (as it can be easily proved by gradually adding water volumes to a fixed cellulose volume: a progressive reduction of the precipitate will in fact show up with increasing volumes of solvents; however, it will remain a precipitate also with a 1000:1 water-cellulose weight ratio).
  • a gradual "bulking" effect will be obtained, which is easily dosable for progressive dose increases.
  • microcellulose will develop through its insolubility an efficient absorbing effect in all those conditions where an excessive intestinal transit speed is caused by intestinal inability to reabsorb water.
  • This condition occurs and has a clinical significance eg. in the case of irritable colon syndrome, characterized by alternating alvus, i.e. repeated alternation of constipation and stools.
  • Such a condition is often related to the intestine intolerance to some sugars available in the aliments that cannot be digested at all, or to an oversensitivity to vegetable long fibers, or both of them.
  • the intestinal bacterial flora will rapidly convert lactose into lactic acid, carbon dioxide and water, stressing both the irritant effect and transit speed, and alternating strong abdominal distention and pains. While the therapy will obviously require a reduction or removal of milk products, introduction of microcellulose according to the present invention has a regulatory effect on the bolus and makes it consistent, however it will not lead to the overdistention phenomena as caused by fibres of vegetable origin, right for the limited swelling capacity of microcellulose.
  • microcellulose does not contain any constituents capable of a further incentive for bacterial degradation with gas production.
  • Microcrystalline cellulose is a polyhydroxyaldheide, thus it has a slight polarity between the terminal portion which is lyophilic and the initial portion which is hydrophilic. In our experiments this characteristic of the molecule allows either an important and irreversible dispersion of oil in water media, or a reduction in capillary water pressures. Thus, reducing the size of oil drops in food introduced by diet and water adhesiveness, the introduction of sufficient amounts of microcrystalline cellulose would improve also gastric emptying. This phenomenon has never been described before. On the contrary, all alimentary fibers are well known and clinically used for the pu ⁇ ose to slow gastric emptying, bloating being the subjective consequence which very frequently leeds to discontinuation of fibers introduction.
  • microcellulose vehiculated in pharmaceutical forms for ingestion (tablets, capsules or granular and/or powder form) is indicated as the main or sole active constituent in preparations for use in all conditions of altered intestinal motility due to insufficient or viceversa excessive water presence, first in the alimentary bolus and then in stools. Due to its insoluble characteristics (unlike soluble methyl-cellulose and carboxymethyl-cellulose) that make it an ideal lyophilic colloid, microcellulose develops a regulatory effect on the solid-fluid ratio during intestinal transit. It is apparent how according to the present invention microcellulose is indicated for use as the main or sole active ingredient in preparations adequately covering either partially or totally the requirements of undigested fibres in the alimentary diet of humans and animals.
  • microcellulose in this frame can be used as an ideal dietetic integrator in all pathologic conditions where fibres assumption is contraindicated since irritation is caused by an excessive length of fibres.
  • microcellulose according to the present invention is indicated as an ideal dietetic integrator in all conditions where the intestinal assumption of fibres should be maintained or increased, but this is contraindicated because of the risk of malabso ⁇ tion induced by them on calcium and iron (eg. osteoporosis, pregnancy, sideropoor anaemia, etc.).
  • microcellulose is an ideal integrator of undigested fibres for its dimensional, chemical-physical and organolectic characteristics, having an ideal regulatory effect in all conditions of decreased intestinal motility and above all in all conditions where other undigested fibrous residues are not tolerated and even contraindicated for therapeutic pu ⁇ oses.
  • microcellulose can also be used as a constituent for association with other molecules, to modulate the preponderant effect of some substances (eg. a strong hydrophilous effect of methyl-cellulose and psyllium) or stress the reducing tensio-active effect of other substances (eg. symeticone).

Abstract

According to the invention, a dimensionally specific physical form of polycellobiose, also called microcrystalline cellulose or microcellulose, is vehiculated in pharmaceutical forms suitable for ingestion (such as capsules, tablets, granula or powder forms, etc.) in order to obtain a regulatory effect on gastro-intestinal transit, in all conditions where cellulose and other fibres may not be well tolerated or are contraindicated.

Description

MICROCELLULOSE-BASED PREPARATIONS
Description
All kind of therapeutic approaches to treatment of constipation have important biases peculiarly on long term treatment schedules. Diphenylmethane (phenolphtalein, pysacodil) and antraquinone containing laxatives of vegetable origin (cascara, senna, rhamnus, danthron, aloe) have been targeted as suitable only for very short period or extemporary treatment of constipation for their potential risks by government health, food and drug agencies of different countries. On the other hand, saline cathartics (magnesium, sodium phosphate and potassium salt) cannot be used chronically and are potentially dangerous because of calcium and water excessive losses, and can thus inducing malabsorption of soluble drugs and vitamins. Their use is limited also by pain as frequent collateral effect. In the last two decades, mainly as a result of epidemiologic studies on large populations, the role of fibres, the main indigestible alimentary constituent, has been focused by nutritionists. This is mainly due to their role in the possible prevention of colon carcinoma as well as to their regulatory effect on dimensions, consistence and speed of intestinal transit. For this reason, dietary fibres have found a wide application in the treatment of constipation. The term dietary fibres is referred to the total natural fibrosic contents available in aliments, mainly of vegetable origin, which cannot be chemically digested by the enzymatic system of humans. One of the nutritional problem lies in the fact that, on average, occidental diets lack a sufficient amount of fibres, due to the treatments that food undergoes during its preparatory stages (as an example, bran is removed from wheat grains when transformed in flour). According to the U.S. National Health and Nutrition
Examination Survey, the average daily fibre introduction in U.S.A. is 1 1 g/die, whereas a reasonable recommendation calls for 20-25 g/die.
Entering more into details, classification of dietary fibres is referred to the residues of indigestible vegetables and can be summarized as follows:
1. cellulose; 2. non-cellulosic fibres.
1. Cellulose
Cellulose is a polysaccharide (C6Hιo05) whose molecular weight ranges from 300.000 to 500.000, formed by linear chains of D- glucose molecules linked together by beta bonds.
Alimentary fibres consist of millions of cellulose molecules linked together in chains, whose length may even reach several tens of centimeters or meters. Beta bonds are undigested by mammals" enzymatic systems (for instance, starch has alpha bonds).
Cellulose is the main structural constituent of vegetable cell walls. It is insoluble in distilled water and acids.
2. Non-cellulosic fibres Non-cellulosic fibres consist of non-cellulosic polysaccharides comprising emicelluloses, pectines, mucillages and other media derived by algae, resins and lignin. Besides water absorption, non-cellulosic fibres have also other collateral effects due to their chelant action as they seem to be able to chelate biliary salts and cholesterol, thus reducing their absoφtion; however, this effect is unfortunately reached also with drugs and minerals, such as iron, calcium and zinc. Further, resins and soluble fibres contained therein may undergo a bacterial digestion in the colon, and elicit short-chain volatile fat acids and gas production (carbon dioxide and methane). The use of mixed alimentary fibres, either cellulosic or not, has become common use in the treatment of constipation, in the form of "bulk forming" laxatives, due to their water retention capability. The size of fibres seems to have a determining action as the longer the fibres are the bulkier will they become with fluid. As a matter of fact, the previous technique uses fibre mixtures of alimentary origin whose chain is the longest possible to maximize the "bulk forming" effect, with all the relevant implications on water retention inside and its chelating effect on various biologic molecules (specifically biliary salts and fat acids). Moreover, the phytate contents of vegetable fibres is significant during calcium and iron based treatments, where phytates have a chelating action that reduces their bioavailability substantially.
The use of methyl-cellulose is known for laxative purposes due to its specific water absoφtion and solubility properties. Methyl-cellulose and carboxymethyl-cellulose derived from it are products obtained by synthesis, which modify the chemical- physical characteristics of cellulose, i.e. from insoluble to soluble in cold water and insoluble in hot water.
Solubility is a function of the number of methylic units used as substituents; the products known on the market have a 1,8 substitution degree, i.e. they contain about 29% methossilic units. Methyl-cellulose and carboxymethyl-cellulose can be converted into gel.
Therefore, the pharmacologic laxative effect according to the known state of art can be summarized as follows:
- increase of alimentary bolus and stools,
- increase of water contents, with accelerated ileum transit,
- increased quantity in the colon of biliary salts available in the stools due to the chelating effect, - eliciting gas production and increased presence of free fat acids due to bacterial digestion of aliments escaped to digestion as they were bulk entrapped and/or of constituents of said alimentary fibres entrapped by the bacterial intestinal flora.
It is the object of the present invention to overcome the problems of the previous technique. In particular, the aim of the research leading to the identification of the present invention was to solve the limit and problems posed by actual knowledge and state of the art, by corresponding to all the following requirements:
- physical not chemical action; - emulsionant action on water-oily interfacies;
- easily controlled, dose-related osmolarity;
- bulk forming, dose related effect;
- no caloric contribution;
- indigestibility by human digestive enzymes - no chemical interaction with drugs.
These characteristics would be appropriate for an ideal regulator of intestinal motility, suitable for acute or chronic safe use. According to the present invention this object is obtained with the use of microcellulose to be vehiculated in pharmaceutical forms suitable for ingestion (tablets, capsules, granular or powder form, etc.) as the sole or main active ingredient in preparations suitable to cover either partially or totally the requirements of alimentary fibres in humans or animals, or in preparations to regulate intestinal transit, preferably suitable for the use in all conditions of altered intestinal motility due to an insufficient or viceversa excessive water retention, first in the alimentary bolus and then in stools, where microcellulose affects in a regulatory manner the solid-fluid ratio during intestinal transit.
Further objects and advantages of the present invention will be apparent from the following detailed description, which is supplied by way of an explanatory but non limiting example. Microcrystalline cellulose or microcellulose is a preparation of fragments of cellulose crystallite units in the form of a non fibrosic powder, containing particles in the form of rigid small bars, whose refraction index is 1.55.
The molecular weight of the basic component, microcellulose, can range as required from 10.000 to 300.000, i.e. between a range of numbers of atoms classified from 104 to IO9, whose dimensions allow a liophile colloidal dispersion. Availability of different molecular weights of microcrystalline cellulose allow to graduate the number of molecule in any given unit of weight, thus to improve or reduce the osmolar effect ofthe product. Examples of how microcrystalline cellulose is synthesised are described in US Patents nos. 2,978,476 and US 3,141,875. Microcrystalline cellulose or microcellulose is featured by its peculiar property of being slightly soluble in diluted alcaline solutions, whereas it is totally insoluble in acids and does not gelify under any conditions.
Therefore, microcellulose is fully inactive in the stomach and just a light solubility can be foreseen in the continuation of the gastrointestinal transit with pH raise. Moreover, unlike methyl- cellulose, microcrystalline cellulose will not dissolve in any water volume.
Chemical-physical characteristics of microcrystalline cellulose to form a sol have provided a new indication for its use as emulsifier, foam-repellent and thickening agent.
However, it is the object of the present invention to use microcellulose to obtain a regulatory effect on intestinal motility due to its chemical-physical characteristics. This has the puφose of obviating to the problems caused by alimentary fibres available so far on the market, such as subordination to water volume, digestion of part of their constituents and often unendurable production of large intestinal gas volumes, their chelating effect con pharmaceutical products and some minerals salts. In addition, according to the present invention, microcellulose is provided for use under those conditions where alimentary fibres are not tolerated, being excessively irritant and eliciting a too fast, frequent and irritant intestinal transit of bolus volume. Microcellulose is not digested by mammals because they have no cellulase, i.e. the enzyme required to break beta bonds between D- glucose molecules. For this reason, microcellulose will not cause, as of itself, any problems related to the digestion of sugars contained in the fibres or alimentary fibres. 7
Due to the relatively small molecular size in respect to cellulosic fibres (containing milions of closely interlaced cellulose units for total macroscopic sizes), microcellulose is also featured by a lower water eagerness and unlike water soluble methyl-cellulose it is insoluble in water.
Therefore, a given quantity of microcellulose will yield a number of molecules as liophile dispersion to the water available with or contained in the aliments, as a fixed proportion of the water- microcellulose ratio (as it can be easily proved by gradually adding water volumes to a fixed cellulose volume: a progressive reduction of the precipitate will in fact show up with increasing volumes of solvents; however, it will remain a precipitate also with a 1000:1 water-cellulose weight ratio). Thus, a gradual "bulking" effect will be obtained, which is easily dosable for progressive dose increases.
Further, microcellulose will develop through its insolubility an efficient absorbing effect in all those conditions where an excessive intestinal transit speed is caused by intestinal inability to reabsorb water. This condition occurs and has a clinical significance eg. in the case of irritable colon syndrome, characterized by alternating alvus, i.e. repeated alternation of constipation and stools. Such a condition is often related to the intestine intolerance to some sugars available in the aliments that cannot be digested at all, or to an oversensitivity to vegetable long fibers, or both of them.
The patient suffers from constipation if fibres are eliminated, whereas he will suffers from diarrhea when vegetables and/or milk products are introduced. Colon irritability, in fact, is often due to a lack of intestinal lactase (i.e. the enzyme capable of separating the lactose unit in two sub-units, namely galactose and glucose). The resulting overosmolarity of the alimentary bolus would anyway lead to an intestinal bolus containing an excessive water volume, all the more if long vegetable fibres are contained therein, which have an enormous swelling capacity.
Moreover, when the bolus reaches the intestine, the intestinal bacterial flora will rapidly convert lactose into lactic acid, carbon dioxide and water, stressing both the irritant effect and transit speed, and alternating strong abdominal distention and pains. While the therapy will obviously require a reduction or removal of milk products, introduction of microcellulose according to the present invention has a regulatory effect on the bolus and makes it consistent, however it will not lead to the overdistention phenomena as caused by fibres of vegetable origin, right for the limited swelling capacity of microcellulose.
Moreover, the reduced length of the particles forming it will not lead to any overdistention phenomena due to formation of large boluses difficult to fraction and having a reduced absoφtion surface; moreover, since the precipitate-dispersion ratio of microcellulose is a function of water volume, there will be a self- regulation between the dispersed and non-dispersed part percentage, suitable to maintain the best possible solid-fluid ratio, i.e. providing a regulatory action. On the contrary, methyl -cellulose and carboxymethyl-cellulose, which are strongly soluble in water, only tend to maintain the water volume present in the intestinal lumen at a maximum level, operating solely as transit or stool bolus accelerators. Unlike alimentary fibres (bran, mucillages, etc.), microcellulose does not contain any constituents capable of a further incentive for bacterial degradation with gas production.
Microcrystalline cellulose is a polyhydroxyaldheide, thus it has a slight polarity between the terminal portion which is lyophilic and the initial portion which is hydrophilic. In our experiments this characteristic of the molecule allows either an important and irreversible dispersion of oil in water media, or a reduction in capillary water pressures. Thus, reducing the size of oil drops in food introduced by diet and water adhesiveness, the introduction of sufficient amounts of microcrystalline cellulose would improve also gastric emptying. This phenomenon has never been described before. On the contrary, all alimentary fibers are well known and clinically used for the puφose to slow gastric emptying, bloating being the subjective consequence which very frequently leeds to discontinuation of fibers introduction.
Therefore, according to the present invention, microcellulose vehiculated in pharmaceutical forms for ingestion (tablets, capsules or granular and/or powder form) is indicated as the main or sole active constituent in preparations for use in all conditions of altered intestinal motility due to insufficient or viceversa excessive water presence, first in the alimentary bolus and then in stools. Due to its insoluble characteristics (unlike soluble methyl-cellulose and carboxymethyl-cellulose) that make it an ideal lyophilic colloid, microcellulose develops a regulatory effect on the solid-fluid ratio during intestinal transit. It is apparent how according to the present invention microcellulose is indicated for use as the main or sole active ingredient in preparations adequately covering either partially or totally the requirements of undigested fibres in the alimentary diet of humans and animals. Therefore, in this frame microcellulose can be used as an ideal dietetic integrator in all pathologic conditions where fibres assumption is contraindicated since irritation is caused by an excessive length of fibres. Likewise, microcellulose according to the present invention is indicated as an ideal dietetic integrator in all conditions where the intestinal assumption of fibres should be maintained or increased, but this is contraindicated because of the risk of malabsoφtion induced by them on calcium and iron (eg. osteoporosis, pregnancy, sideropoor anaemia, etc.). According to the above description the characteristics of the present invention will be apparent, as it is obvious also for its advantages. Specifically, as described above it will be apparent how microcellulose is an ideal integrator of undigested fibres for its dimensional, chemical-physical and organolectic characteristics, having an ideal regulatory effect in all conditions of decreased intestinal motility and above all in all conditions where other undigested fibrous residues are not tolerated and even contraindicated for therapeutic puφoses. Finally, microcellulose can also be used as a constituent for association with other molecules, to modulate the preponderant effect of some substances (eg. a strong hydrophilous effect of methyl-cellulose and psyllium) or stress the reducing tensio-active effect of other substances (eg. symeticone).

Claims

Claims
1. The use of microcellulose, to be vehiculated in pharmaceutical forms suitable for ingestion (tablets, capsules, granular and powder form, etc.) as the sole or main active ingredient in preparations suitable to cover either partially or totally the requirements of undigested fibres in the diet of humans or animals.
2. The use of microcellulose according to Claim 1 in preparations suitable to act as a dietetic integrator in all pathologic conditions, where fibres assumption is contraindicated due to irritation caused by an excessive fibre size.
3. The use of microcellulose according to Claim 1 in preparations suitable to act as a dietetic integrator in all pathologic conditions, where the intestinal assumption of fibres should be maintained or increased, but is contraindicated because of the risk of malabsoφtion induced by them on calcium and iron (eg. osteoporosis, pregnancy, sideropoor anaemia, etc.).
4. The use of microcellulose according to Claim 1 in preparations having a regulatory effect on the solid-fluid ratio during intestinal transit, in all pathologic conditions of altered intestinal motility due to insufficient or viceversa excessive water presence first in the alimentary bolus and then in stools.
5. The use of microcellulose according to one or more of the above Claims, for association with other molecules to modulate their preponderant effect or stress the reducing tensio-active effect of other substances.
6. Preparations having a regulatory effect on intestinal transit, in particular suitable for use in all conditions of altered intestinal motility due to insufficient or viceversa excessive water presence, first in the alimentary bolus and then in stools, characterized in that they comprise microcellulose in pharmaceutical form suitable for ingestion (tablets, capsules, granular and powder form), as the sole or main active ingredient having a regulatory effect on the solid- fluid ratio during intestinal transit.
7. Preparations suitable to cover either partially or totally the requirements of undigested fibres in the diet of humans or animals, characterized in that they comprise microcellulose in pharmaceutical forms suitable for ingestion (tablets, capsules, granular and powder form) as the sole or main active ingredient.
8. Preparations comprising microcellulose according to the above description and for the puφoses as specified.
PCT/EP1996/004961 1995-11-14 1996-11-13 Microcellulose-based preparations WO1997017976A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU76232/96A AU7623296A (en) 1995-11-14 1996-11-13 Microcellulose-based preparations
EP96939020A EP0861083A1 (en) 1995-11-14 1996-11-13 Microcellulose-based preparations
JP9518574A JP2000502048A (en) 1995-11-14 1996-11-13 Microcellulose preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95TO000917A IT1290792B1 (en) 1995-11-14 1995-11-14 MICROCELLULOSE BASED PREPARATIONS
ITTO95A000917 1995-11-14

Publications (1)

Publication Number Publication Date
WO1997017976A1 true WO1997017976A1 (en) 1997-05-22

Family

ID=11413961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/004961 WO1997017976A1 (en) 1995-11-14 1996-11-13 Microcellulose-based preparations

Country Status (6)

Country Link
EP (1) EP0861083A1 (en)
JP (1) JP2000502048A (en)
AR (1) AR008987A1 (en)
AU (1) AU7623296A (en)
IT (1) IT1290792B1 (en)
WO (1) WO1997017976A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993551B2 (en) 2002-10-16 2015-03-31 Alan Ferguson Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023104A (en) * 1960-07-05 1962-02-27 American Viscose Corp Food compositions incorporating cellulose crystallite aggregates
EP0317079A2 (en) * 1987-11-19 1989-05-24 Orlando A. Battista High-fiber, expandable, dry-mixed compositions
JPH01319421A (en) * 1988-06-17 1989-12-25 Hajime Inamoto Composition for improving constipation, promoting dejection and improving fecal property
US5342636A (en) * 1992-05-05 1994-08-30 Bakshi Amarjit S Process for modifying a fibrous bulking agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023104A (en) * 1960-07-05 1962-02-27 American Viscose Corp Food compositions incorporating cellulose crystallite aggregates
EP0317079A2 (en) * 1987-11-19 1989-05-24 Orlando A. Battista High-fiber, expandable, dry-mixed compositions
JPH01319421A (en) * 1988-06-17 1989-12-25 Hajime Inamoto Composition for improving constipation, promoting dejection and improving fecal property
US5342636A (en) * 1992-05-05 1994-08-30 Bakshi Amarjit S Process for modifying a fibrous bulking agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 014, no. 118 (C - 0697) 6 March 1990 (1990-03-06) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993551B2 (en) 2002-10-16 2015-03-31 Alan Ferguson Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof

Also Published As

Publication number Publication date
JP2000502048A (en) 2000-02-22
EP0861083A1 (en) 1998-09-02
AU7623296A (en) 1997-06-05
AR008987A1 (en) 2000-03-08
IT1290792B1 (en) 1998-12-10
ITTO950917A0 (en) 1995-11-14
ITTO950917A1 (en) 1997-05-14

Similar Documents

Publication Publication Date Title
Behera et al. Konjac glucomannan, a promising polysaccharide of Amorphophallus konjac K. Koch in health care
Cassidy et al. Effect of soluble dietary fibre on postprandial blood glucose response and its potential as a functional food ingredient
Singh et al. Prebiotic potential of oligosaccharides: A focus on xylan derived oligosaccharides
Zhu et al. Functional polysaccharides of carob fruit: a review
Kumar et al. Dietary roles of non-starch polysachharides in human nutrition: a review
JP5898171B2 (en) Carbohydrate mixture
Rose et al. Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern
EP2188315B1 (en) Method of preparing fibre-containing pectin product and pectin products hereof
Qiang et al. Health benefit application of functional oligosaccharides
Brownlee et al. Alginate as a source of dietary fiber
US5840860A (en) Fatty acid delivery system comprising a hydrolyzable bond
US7067498B2 (en) Polymer controlled induced viscosity fiber system and uses thereof
Liu et al. The physicochemical properties, in vitro binding capacities and in vivo hypocholesterolemic activity of soluble dietary fiber extracted from soy hulls
Gomez et al. Manufacture and properties of glucomannans and glucomannooligosaccharides derived from konjac and other sources
Margareta et al. Importance of processing for physico-chemical and physiological properties of dietary fibre
Arora et al. Plant-based polysaccharides and their health functions
WO1997017976A1 (en) Microcellulose-based preparations
Rose et al. Overview of dietary fiber and its influence on gastrointestinal health
Robinson et al. Nutritional benefits of larch arabinogalactan
Meyer et al. Non‐digestible oligosaccharides and polysaccharides: their physiological effects and health implications
WO2010140182A1 (en) Food compositions comprising flour, glucomannan and a mixture of soluble prebiotic fibres and process for the preparation thereof
JP2015514411A (en) Combination of β-glucan and arabinoxylan
Bhat et al. Cereals as functional ingredients in meat and meat products
Purohit et al. Isabgol: a herbal remedy
Rose Autohydrolytic production of feruloylated arabinoxylan hydrolysates from cereal processing coproducts for food applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 518574

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996939020

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996939020

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996939020

Country of ref document: EP